Global Drug-Eluting Stents Industry

• Publication date: May 2012
• Report size: 282 pages

This report analyzes the worldwide markets for Drug-Eluting Stents in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of the World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 39 companies including many key and niche players such as Abbott Vascular, Boston Scientific, Inc., ...

This report analyzes the worldwide markets for Drug-Eluting Stents in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of the World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 39 companies including many key and niche players such as Abbott Vascular, Boston Scientific, Inc., Biosensors International Pte Ltd., Medtronic, Inc., and MIV Therapeutics Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Global Cardiovascular Devices Industry

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3


II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW II-1
Recession Plummets Global DES Market II-1
Major Issues and Trends II-2
Recession Hits Cardiovascular Device Makers II-2
Changing Fortunes in the Global DES Industry II-2
Global Market Recovers From Safety Issue Shambles II-2
Competition Intensifies as New Products Make Way in to the
Market II-3
Drug-Eluting Stents Transforming the Face of Interventional
Cardiology Market II-3
Table 1: Global Stents Market by Type (2011): Percentage
Breakdown of Value Sales for Drug-Eluting Stents and
Bare-Metal Stents (includes corresponding Graph/Chart) II-4
Concerns over Adverse Effects Remain A Major Snag II-4
Potential Decline in Hospital Revenues II-4
Shift in Pricing Models to Increase Innovation Levels II-5
Glaring Lack of Health-Related Initiatives the World Over II-5
Bioabsorbable Stents - Abbott Makes a Headstart with Absorb II-5

2. COMPETITIVE LANDSCAPE II-7
A Brief Introduction to DES II-7
Suitable Patient Types for Drug-Eluting Stents II-7
J&J Exit from DES Market Improves Prospects for Competitors II-7
Drug-Eluting Stents - Competitive Landscape II-8
World Drug-Eluting Stents Market (2002-2012): DES Brands
Launched by Major Manufacturers- Abbott Vascular Inc.,
Boston Scientific Corp., Cordis (Johnson & Johnson),
Medtronic Inc., and Intersect Ent II-9
Boston Scientific Leads Global DES Market, Abbott Closes In II-9
Table 2: World Drug Eluting Stents Market (2010): Market
Share Breakdown of Value Sales by Leading Players - Boston
Scientific, Abbott, Medtronic, and Others (includes
corresponding Graph/Chart) II-10
Xience and Promus Take the Lead II-10
Table 3: World Drug Eluting Stents Market (2010): Market
Share Breakdown of Value Sales by Leading Brands - Xience V,
Promus/Element, Taxus, Endeavor and Others (includes
corresponding Graph/Chart) II-10
Major DES Drugs Available in the Market II-11
Sirolimus II-11
Paclitaxel II-11
Everolimus II-11
Zotarolimus II-11
Biolimus II-11
Other Treatments Available for Treating In-Stent Restenosis II-12
Select Leading Drug-Eluting Stent Products in the Market II-12
XIENCE V (Abbott) II-12
PROMUS® (Boston Scientific) II-12
XIENCE PRIME (Abbott) II-12
TAXUS® Liberté® Atom™ (Boston Scientific) II-12
ENDEAVOR (Medtronics) II-13
TAXUS (Boston Scientific) II-13

3. CORONARY STENTING - AN INSIGHT II-14
Cardiovascular Diseases - A Brief Description II-14
Table 4: World Market for Cardiovascular Therapies (2011):
Percentage Share Breakdown of Value Sales by Product
Category-Drug-Eluting Stents, Cardiac Resynchronization
Therapy, Cardiac Markers, Portable Automated External
Defibrillators, and Angiogenesis/Gene Therapy (includes
corresponding Graph/Chart) II-14
Coronary Heart Disease II-15
Traditional Methods of Treating Blockage of Coronary Arteries II-15
Percutaneous Transluminal Coronary Angioplasty (PTCA) II-15
Coronary Artery Bypass Graft (CABG) II-15
Restenosis II-15
Evolution of Coronary Stents as a Replacement for Traditional
Methods II-15
What are Coronary Stents? II-16
How is Coronary Stenting Performed - Procedure II-16
Risks and Problems Associated with Placing a Stent II-16
Restenosis Still Pervasive Even after the Use of Stents II-16
Market Analysis for Coronary Stents II-16
By Region/Country II-17
Table 5: World Market for Coronary Stents (2011): Percentage
Share Breakdown of Value Sales by Region/Country -US, Japan,
Europe, Japan, and Rest of World (includes corresponding
Graph/Chart) II-17
In-Stent Restenosis - Outcome of Bare Metal Stents II-17
In-Stent Restenosis - Definition II-17
Causes of In-Stent Restenosis II-17

4. COST AND PRICE ECONOMICS II-18
Cost Evaluation of DES II-18
Initial Procedural Costs Remain High II-18
Table 6: Average Price Per DES Unit for the Period 2004-2005 II-18

Table 7: Worldwide Average Stent Prices (2002-2005):
Breakdown of Regions by Drug Eluting Stents and Bare Metal
Stents II-18
Follow-Up Costs Provide Relief II-19
Table 8: A Comparative Presentation of Long-Term Costs of
DES and CABG II-19
Conversion of CABG Procedures to DES II-19
Impact of DES on Indirect Costs II-19

5. RESEARCH AND DEVELOPMENT INITIATIVES - A HISTORIC PERSPECTIVE
BUILDER II-20
Boston Completes European and Intercontinental Enrollment Phases II-20
Medtronic To Start Clinical Study II-20
Guidant Accomplishes Patient Enrollment II-20
Abbott Receives FDA Approval for Initiation of ZoMaxx Clinical
Trials II-20
Medtronic Commences Endeavor III Clinical Trial II-21
MIV Therapeutics Completes Drug-Eluting Stent Coating R&D Program II-21
Guidant Conducts First Implant as Part of Drug Eluting Stent
Trial II-21
Medtronic’s Endeavor Drug Eluting Stent Shows Positive Results II-21
Cypher™ Coronary Stent Trials Show Restenosis Rates Decline by
5.1% II-22
Boston Scientific Demonstrates Positive Results for Taxus IV
Clinical Trial II-22
Medtronic Initiates Endeavor II Clinical Trials for Endeavor
Drug Eluting Stent II-22
Guidant’s Clinical Trials for Coronary Stent Demonstrates
Positive Results II-22

6. CLINICAL TRIALS UNDERTAKEN FROM 2002-2007 II-23
MIV Commences Clinical Trials of HC Stent II-23
XTNT Voiced CUSTOM III Trial Program of NX™ DES System II-23
Dynatek Completes DES Coating Durability Trial II-23
STEALTH Trial II-23
SIROCCO Trial II-24
Cook Trial II-24
ZoMAXX Trial II-24
Ravel Trial II-24
Sirius Trial II-24
C - Sirius Trial II-25
E - Sirius Trial II-25
Taxus I through VI Clinical Trials II-25
Other Clinical Trials II-25

7. PRODUCT INNOVATIONS/INTRODUCTIONS II-26
Abbott Receives European Clearance for Bioabsorbable Stent II-26
NIMS Develops Am80 Drug Eluting Stent II-26
Cook Medical Unveils New CE Marked Zilver PTX Drug-Eluting
Peripheral Stent II-26
Medtronic Rolls Out Driver Sprint RX Coronary Stent System II-27
Boston Scientific Launches TAXUS Liberte DES In Japan II-27

8. PRODUCT INNOVATIONS/INTRODUCTIONS - A HISTORIC PERSPECTIVE BUILDER II-28
Medtronic Unveils Endeavor Sprint Drug-Eluting Stent in The US II-28
CeloNova Unveils CATANIA™ Stent System with NanoThin Polyzene®-F II-28
Abbott Launches Xience V Drug-Eluting Coronary Stent in Europe II-28
Boston Introduces Taxus(R) Express2(TM) in Japan II-28
Cordis Brings Advanced Drug-Eluting Stent II-29
Sorin Unveils Enhanced Janus Flex in Europe II-29
EUREKA Develops Latest Generation of Drug- Eluting Stent II-29
MIV Therapeutics Develops New Drug Eluting Coating Technology
in Canada II-30
Medtronic to Launch Endeavor DES in Europe II-30
DISA Vascular (Pty) Ltd Introduces ChromoFlex in Europe II-30
Boston Scientific Introduces Taxus Liberté Drug Eluting Stent
in Europe II-31
Boston Scientific Introduces Innovative Drug-Eluting Stent,
Taxus in the US Market II-31

9. RECENT INDUSTRY ACTIVITY II-32
Boston Scientific Obtains CE Mark Approval for TAXUS Element™ II-32
Biosensors Takes Over Cardiomind II-32
Tryton Medical Implants First Tryton® in Austria and Portugal II-32
Medtronic to Take Over Invatec II-32
Abbott Obtains Approval for XIENCE V Stent System in Japan II-33
Boston Scientific Obtains Approval for Promus Stent In Japan II-33
Opto Circuits (India) Obtains CE Mark Approval for Taxcor Plus II-33
Abbott Obtains Approval for Additional Indications of Xience V
and Xience Prime II-34
Bayer MaterialScience to Acquire PolyBioMed II-34
Boston Scientific Obtains Health Canada Approval for PROMUS® II-34
Abbott Labs to Introduce XIENCE V Stent in China II-34
Abbott Obtains Approval for XIENCE V® from Health Canada II-35
Boston Scientific Obtains FDA Approval for TAXUS® Liberte®
Atom™ Stent II-35
Medtronic Obtains CE Mark Approval for Endeavor DES II-35
Biosensors International Group Receives CE Mark Approval for
BioMatrix II-36
Medtronic Receives Approval for Endeavor Drug-eluting Stent in
Japan II-36
Boston Scientific Obtains Japanese Approval for TAXUS®
Liberte® Atom™ II-36
XTENT Receives CE Mark Approval for CUSTOM NX DES II-36
Maxcor Lifescience Inks Strategic Cooperation Agreement with
Micell Technologies II-37
Boston Scientific Snaps Up Labcoat II-37

10. INDUSTRY ACTIVITY - A HISTORIC PERSPECTIVE BUILDER II-38
Medtronic Commences PROTECT Comparative Study in US II-38
B.Braun to Invest in its India based Operations II-38
Medtronic Secures TDP Approval for Endeavor Zotarolimus
Eluting Coronary Stent II-38
Medtronic Receives US FDA Approval for Endeavor Drug-Eluting
Stent II-39
Novation and Medtronic Ink National Agreement II-39
MIV Therapeutics Acquires Biosync Scientific II-39
J & J Acquires Conor Medsystems II-39
FDA Approves Boston Scientifis’s Taxus Stent with Extended
Shelf Life II-40
Lombard Collaborates With S&N II-40
India Establishes Asia’s first Catheter and Stent Unit. II-40
Abbott Requests FDA Approval for Xience II-40
Brookwood and TTV Start Joint Venture II-40
SurModics Acquires Brookwood Pharmaceuticals, Inc II-41
ARIAD Collaborates with ICON Medical II-41
Biosensors Acquires 50% Stake in JWMS II-41
Cordis’ Cypher Select™ Plus Receives Approval in Europe II-41
Boston Scientific Acquires Guidant for $27 Billion, Abbott
Gets Guidant’s Vascular and Cardiac Therapies Businesses as
Part of Deal II-42
Conor COSTAR II Receives US FDA Approval II-42
Abbott Expands Vascular Sites in Ireland II-42
Medtronic’s Endeavor® Attains Reimbursement Approval in France II-42
SurModics Offers License for Hydrophilic Technology to Devax II-42
Conor obtains License for Novartis’ Pimecrolimus II-43
Medtronics Makes Final PMA Submission for Endeavor II-43
Volcano Collaborates with CRF, Cardialysis and Stanford
University II-43
Boston’s PROMUS Receives CE Mark Approval II-43
SurModics and X-Cell Inks Licensing Agreement II-44
Medtronic Receives Regulatory Approval for Endeavor (R) II-44
Medtronics’ Endeavor Obtains Chinese Regulatory Approval II-44
Biosensors Collaborates with JW Medical II-44
Biosensors and Weigao To Consolidate Joint Venture II-44
Biotronik Enters Multi-Drug Deal with Novartis II-45
MIVT Enters Collaboration Deal with SMT II-45
SMT’s Infinnium Paclitaxel System Receives CE Mark II-45
Guidant’s Xience V Receives European Approval II-45
Medtronic Files Initial PMA Module TO US FDA II-46
Boston Scientific Receives European Approval for TAXUS(R) II-46
Biosensors Attains US Patent Covering DES Technology II-46
MediVas LLC and Estracure Inc Sign Agreement for Development
of DES II-46
Relisys Medical of India Finalizes Deal with Germany Based
Blue Membranes II-46
X-cell Medical Enrolls for Clinical Trial of ETHOS I Estradiol
Eluting Stent. II-47
Biosensors International Group Receives CE Approval for First
DES, Axxion II-47
Boston Scientific Corp Receives CE Mark Approval for Marketing
Larger Stent Sizes II-47
Medtronic Receives CE Mark Approval for Commercial Sale of
Endeavor DES in Europe II-47
Biosensors International Opens New Interventional Cardiology
Unit in Singapore II-48
Johnson & Johnson Recalls Cypher Drug-Eluting Stents II-48
Boston Scientific Buys Out Precision Vascular Systems II-48
Implant Sciences and CardioTech International enter into
Partnership with CorNova II-48
Avantec Vascular Corporation Signs Agreement with Novartis
Pharma AG II-48
Guidant and Cordis Enter into Promotion Agreement II-49
Genvec Collaborates with Cordis II-49
Cordis Receives Approval from Japanese Ministry of Health II-49
Boston Scientific Modifies Production of Taxus Drug-Eluting Stent II-49
Guidant Acquired CE Mark Approval for Multi-Link Bifurcation
Stent System II-50
Boston Scientific Receives Reimbursement Approval from French
Government II-50
Boston Scientific Withdraws Consortium of Drug-Coated Stents II-50

11. FOCUS ON SELECT GLOBAL PLAYERS II-51
Abbott Vascular (USA) II-51
Boston Scientific, Inc. (USA) II-51
Biosensors International Pte Ltd. (Singapore) II-52
Medtronic, Inc.(USA) II-52
MIV Therapeutics, Inc. (Canada) II-52

12. GLOBAL MARKET PERSPECTIVE II-54
Table 9: World Recent Past, Current and Future Analysis for
Drug-Eluting Stents by Geographic Region - US, Japan, Europe
and Rest of the World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) II-54

Table 10: World Historic Review for Drug-Eluting Stents by
Geographic Region - US, Japan, Europe and Rest of the World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-55

Table 11: World 15-Year Perspective for Drug-Eluting Stents
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Japan, Europe and Rest of the World Markets for Years
2003, 2011, & 2017 (includes corresponding Graph/Chart) II-56


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Issues and Trends III-1
US Healthcare Ideology III-1
The Important Role of Medicaid in the US III-1
Boston Leads the DES Market III-1
Table 12: US Drug Eluting Stents Market (2011): Market
Share Breakdown by Leading Players - Boston Scientific,
Abbott, Medtronic, and Johnson & Johnson (includes
corresponding Graph/Chart) III-2

Table 13: US Drug Eluting Stents Market (2011): Market
Share Breakdown by Leading Brands - Xience V,
Promus/Element, Taxus, Cypher, and
Endeavor/Resolute(includes corresponding Graph/Chart) III-2
Drug-Eluting Stents Launched in the US by Major
Manufacturers (2003-2012) III-2
Select Leading DES Products in the Market III-3
Xience V - The Leader III-3
Taxus and Promus- The Other Leading DES III-3
Regulatory Environment III-3
FDA Framework III-3
FDA Approvals III-3
B.Market Analytics III-6
Table 14: The US Recent Past, Current and Future Analysis
for Drug-Eluting Stents Analyzed with Annual Sales Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-6

Table 15: The US Historic Review for Drug-Eluting Stents
Analyzed with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) III-7

2. JAPAN III-8
A.Market Analysis III-8
Healthcare System in Japan III-8
Table 16: Japanese Market for Drug Eluting Stents
(2005-2007): Market Share Breakdown of Sales Revenue by
Major Players- Johnson & Johnson Boston Scientific, and
Medtronic III-8
B.Market Analytics III-9
Table 17: Japanese Recent Past, Current and Future Analysis
for Drug-Eluting Stents Analyzed with Annual Sales Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-9

Table 18: Japanese Historic Review for Drug-Eluting Stents
Analyzed with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) III-10

3. EUROPE III-11
A.Market Analysis III-11
Issues and Trends III-11
Reimbursement Woes Continue in Europe III-11
Reimbursement - A Major Hurdle in European Market
Penetration of DES III-11
Slow Market Penetration of New Medical Devices in Europe III-11
Taxus - Leading the European Stent Market III-11
Healthcare System in Europe III-11
B.Market Analytics III-12
Table 19: European Recent Past, Current and Future Analysis
for Drug-Eluting Stents by Geographic Region - France,
Germany, Italy, UK, Spain and Rest of the World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) (includes corresponding Graph/Chart) III-12

Table 20: European Historic Review for Drug-Eluting Stents
by Geographic Region - France, Germany, Italy, UK, Spain and
Rest of the Europe Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-13

Table 21: European 15-Year Perspective for Drug- Eluting
Stents by Geographic Region - Percentage Breakdown of Dollar
Sales for France, Germany, Italy, UK, Spain and Rest of
Europe Markets for Years 2003, 2011 and 2017 (includes
corresponding Graph/Chart) III-14

3a. FRANCE III-15
A.Market Analysis III-15
Healthcare System in France III-15
B.Market Analytics III-15
Table 22: French Recent Past, Current and Future Analysis
for Drug-Eluting Stents Analyzed with Annual Sales Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-15

Table 23: French Historic Review for Drug-Eluting Stents
Analyzed with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) III-16

3b. GERMANY III-17
A.Market Analysis III-17
Healthcare Policies in Germany III-17
Lower Market Penetration of DES III-17
B.Market Analytics III-18
Table 24: German Recent Past, Current and Future Analysis
for Drug-Eluting Stents Analyzed with Annual Sales Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-18

Table 25: German Historic Review for Drug-Eluting Stents
Analyzed with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) III-19

3c. ITALY III-20
A.Market Analysis III-20
Italian Healthcare System III-20
Local Healthcare Agencies III-20
National Health System in Italy III-20
B.Market Analytics III-21
Table 26: Italian Recent Past, Current and Future Analysis
for Drug-Eluting Stents Analyzed with Annual Sales Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-21

Table 27: Italian Historic Review for Drug-Eluting Stents
Analyzed with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) III-22

3d. THE UNITED KINGDOM III-23
A.Market Analysis III-23
National Health System in the UK III-23
B.Market Analytics III-23
Table 28: The UK Recent Past, Current and Future Analysis
for Drug-Eluting Stents Analyzed with Annual Sales Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-23

Table 29: The UK Historic Review for Drug- Eluting Stents
Analyzed with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) III-24

3e. SPAIN III-25
A.Market Analysis III-25
Healthcare System in Spain III-25
B.Market Analytics III-25
Table 30: Spanish Recent Past, Current and Future Analysis
for Drug-Eluting Stents Analyzed with Annual Sales Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-25

Table 31: Spanish Historic Review for Drug-Eluting Stents
Analyzed with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) III-26

3f. REST OF EUROPE III-27
Market Analytics III-27
Table 32: Rest of European Recent Past, Current and Future
Analysis for Drug-Eluting Stents Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) III-27

Table 33: Rest of European Historic Review for Drug-Eluting
Stents Analyzed with Annual Sales Figures in US$ Million for
Years 2003 through 2008 (includes corresponding Graph/Chart) III-28

4. REST OF WORLD III-29
A.Market Analysis III-29
Chinese Drug-Eluting Stents Market Witnesses Robust Growth III-29
B.Market Analytics III-29
Table 34: Rest of the World Recent Past, Current and Future
Analysis for Drug-Eluting Stents Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-29

Table 35: Rest of World Historic Review for Drug- Eluting
Stents Analyzed with Annual Sales Figures in US$ Million for
Years 2003 through 2008 (includes corresponding Graph/Chart) III-30


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 39 (including Divisions/Subsidiaries - 46)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 26
Canada 3
Japan 1
Europe 11
Germany 2
The United Kingdom 3
Italy 1
Rest of Europe 5
Asia-Pacific (Excluding Japan) 4
Africa 1
------------------------------------------